SQI Diagnostics Expanding Its Proprietary Rapid Diagnostic Testing Portfolio Targeting Organ Transplant, Autoimmune Disease and Serological Testing

September 9, 2020

SQI Diagnostics, Inc., is a precision medicine company that discovers, develops, manufactures, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients, and consumers worldwide.

Today they announced it is expanding its proprietary rapid diagnostic testing portfolio targeting organ transplant, autoimmune disease, and serological testing.

SQI Diagnostics, Inc. CEO Mr. Robert L. Chioini stated, “Within our organ transplant, autoimmune disease, and serological testing business units we have multiple products in clinical development, and we believe these advanced tests have the potential to offer patients and consumers significant benefit once they receive regulatory approval. Our COVID-19 At-home Antibody Test Kit and our COVID-19 Patient Triage Test are currently a top priority. We will provide more detail on our novel diagnostics, their clinical progress, and our commercialization efforts shortly.”

Mr. Chioini further stated, “Rapid diagnostic testing that is accurate and widely available is now more important than ever. It is intended that SQI’s direct-to-consumer diagnostic test kits will provide access to convenient, reliable, medical tests for use at home and empower people to improve their health outcomes, while our patient-based diagnostics will enable clinicians to provide fast effective treatment in the healthcare setting. SQI’s unique strategy of merging innovative diagnostics with differentiated health management services will enable us to provide comprehensive support for healthcare professionals, patients, and consumers across the globe.”

Exit mobile version